New drug combo aims to tackle tough pancreatic cancer
NCT ID NCT05497778
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This early-phase trial is testing whether adding an experimental drug called IM156 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and tolerable for people with advanced pancreatic cancer. The study involves 19 participants and primarily looks at side effects. It is being run by M.D. Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IM156 (an experimental drug) plus gemcitabine and nab-paclitaxel (standard chemotherapy)
What this could lead to
If it works, this could point toward a more effective treatment option for advanced pancreatic cancer.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not yet on effectiveness. The combination may cause significant side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.